– SWEDEN, Malmö – Trialbee AB, whose patient recruitment and engagement platform has helped accelerate the development of COVID-19 vaccines, today announced that Matt Walz has been named as CEO to coincide with the appointment of Dr. Lollo Eriksson as Chief Strategy Officer.
Dr. Eriksson has been the CEO during the global expansion and rapid period of growth over the last three years.
“I am pleased and thankful for the support the Trialbee Board of Directors have been providing in the search of a new and strong long-term technology experienced leader for the company,” said Lollo Eriksson. “I am thrilled to work with Matt and continue developing our existing and new strategic approaches and partnerships to realize the best quality and value to our customers and shareholders.”
“Needless to say, we are thankful to Lollo for his contribution and commitment over the last years, which has positioned Trialbee as one of the global leaders in patient recruitment and engagement solutions. The appointment of Matt as Trialbee’s new CEO is perfectly timed. The company is experiencing a rapid scale-up and the technology platform is deepening its scope across multiple data sources. Matt’s extensive technology and software development expertise combined with his leadership and business development track-record will accelerate our growth initiatives, with particular emphasis on strategic alliances and global sales presence,” said Executive Chairman, Daniel Spasic.
These new appointments will strengthen Trialbee’s leadership as the company continues to innovate its data-powered platform and simplify the patient journey in clinical research through digital patient matching and engagement.
About Matt Walz
Mr. Walz has more than 20 years of experience building innovative software platforms and providing strategic leadership in the life sciences area, including a decade of strategic development and plan execution at life science technology companies. Mr. Walz co-founded and served as Chief Strategy Officer and CTO of NextDocs Corporation, which became a leader in regulated content management for Life Sciences’ clinical, regulatory, and quality processes. NextDocs was acquired by Aurea Software in 2015, a move that Mr. Walz was instrumental in achieving.
“The pandemic has made the world aware of the importance of clinical trials, and the critical role they play in connecting new drugs, therapies, and devices with the patients that need them most,” said Matt Walz. “I am humbled by the opportunity to lead Trialbee’s strong management team as we work to achieve the mission of simplifying the patient journey in clinical research through digital patient matching and engagement.”
Mr. Walz received a BS Degree in Computer Science and an MBA, both from the University of Delaware.
About Trialbee
Trialbee is a world-leading technology provider in patient matching and engagement using advanced data science techniques and Real-World Data, empowering patients to participate in clinical trials as one option of care. Founded in 2010, Trialbee has continuously innovated patient-centric technology solutions for global clinical trials in its commitment to solving for costly slow patient recruitment and large numbers of dropouts. The Trialbee solution is proven to accelerate patient recruitment and maintain engagement by incorporating data-driven solutions in clinical trials and optimizing protocol design and site selection. Trialbee – Dedicated to patients; driven by science; and powered by data.
For more information: https://trialbee.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
